INTRODUCTION
Myopathies are disorders affecting the channel, structure, or metabolism of skeletal muscle. Myopathies can be distinguished from other disorders of the motor unit, including the neuromuscular junction, peripheral nerve, or motor neuron, by characteristic clinical and laboratory features. Therefore, the first goal in approaching patients with a suspected muscle disease is to determine the correct site of the lesion. Once the lesion is localized to the muscle, the next step is to identify whether the myopathy is caused by a defect in the muscle channel, muscle structure, or a dysfunction in muscle metabolism. The second goal is to determine the cause of the myopathy. In general, myopathies can be classified into acquired or hereditary disorders (Box 1).
Finally, the third goal in the authors' approach is to determine if there is a specific treatment and, if not, to optimally manage the patients' symptoms in order to maximize their functional abilities and enhance their quality of life.
CLINICAL EVALUATION
The most important component of evaluating patients with a suspected myopathy is obtaining a comprehensive medical history. The history should allow the clinician to make a reasonable preliminary diagnosis that places patients into one of the categories in Box 1. The findings on the physical examination, in particular the distribution of muscle weakness, should provide additional information in determining the correct diagnosis. The results of laboratory studies (blood tests, electrodiagnostic studies, muscle biopsy, molecular genetic studies) then play a confirmatory diagnostic role. [1] [2] [3] [4] The first step in this clinical approach is to ask 6 key questions regarding the patients' symptoms.
differ from cramps in that they usually last longer and are electrically silent with needle electromyography. Muscle contractures should not be confused with fixed tendon contractures. Muscle disorders that are associated with contractures are listed in Box 4.
Myotonia is caused by repetitive depolarization of the muscle membrane and results in impaired relaxation of muscle after forceful voluntary contraction. Myotonia most commonly involves the eyelids and hands. As a result, patients may complain of muscle stiffness or tightness resulting in difficulty releasing their handgrip after a handshake, unscrewing a bottle top, or opening their eyelids if they forcefully shut their eyes. Myotonia classically improves with repeated exercise. In contrast, patients with paramyotonia congentia demonstrate paradoxic myotonia in that symptoms are typically worsened by exercise or repeated muscle contractions. Exposure to cold results in worsening of both myotonia and paramyotonia. The muscle disorders associated with muscle stiffness are listed in Box 5. Sometimes patients with myotonia also complain of myalgias and fatigue.
Myoglobinuria is caused by the excessive release of myoglobin from muscle during periods of rapid muscle destruction (rhabdomyolysis) and is a relatively uncommon manifestation of muscle disease. Severe myoglobinuria can result in renal failure caused by acute tubular necrosis. If patients complain of exercise-induced weakness and myalgias, they should be asked if their urine has ever turned cola colored or red during or after these episodes. Isolated episodes or myoglobinuria, particularly occurring after unaccustomed strenuous exercise, are frequently idiopathic, whereas recurrent episodes are usually caused by an underlying metabolic myopathy (Box 6).
What is the Temporal Evolution?
It is obviously important to determine the onset, duration, and evolution of patients' symptoms and signs of muscle disease. Did the weakness (or other symptoms) first manifest at birth, or was the onset in the first, second, third, or later decade (Box 7)? Identifying the age that symptoms began can provide crucial information leading to the correct diagnosis. For example, the symptoms of Duchenne muscular dystrophy are usually identified by 3 years of age, whereas most facioscapulohumeral and limb-girdle muscular dystrophies (LGMD) begin in adolescence or later. For further discussion of these diseases, the reader is referred to the corresponding Pattern Approach to Myopathy articles by Wicklund and Kissel in this issue. Of the inflammatory myopathies, dermatomyositis occurs in children and adults; polymyositis rarely occurs in children as a benign childhood myositis but is primarily at any decade in the adult years; and inclusion body myositis occurs most commonly in the elderly.
It is also imperative to determine the evolution and duration of the disease. Myopathies can present with either constant weakness (inflammatory myopathies, muscular dystrophies) or episodic periods of weakness with normal strength interictally (metabolic myopathies caused by certain glycolytic pathway disorders, periodic paralysis). The episodic disorders are characterized by acute loss of strength that can return to normal within hours or days. The tempo of the disorders with constant weakness can vary from (1) acute or subacute progression in some inflammatory myopathies (dermatomyositis and polymyositis), (2) chronic slow progression over years (most muscular dystrophies), or (3) nonprogressive weakness with little change over decades (congenital myopathies). Finally, both constant and episodic myopathic disorders can have symptoms that may be monophasic or relapsing. For example, polymyositis can occasionally have an acute monophasic course with complete resolution of strength within weeks or months. Patients with periodic paralysis or metabolic myopathies can have recurrent attacks of weakness over many years, whereas patients with acute rhabdomyolysis caused by cocaine may have a single episode.
Is There a Family History of a Myopathic Disorder?
Because many myopathies are inherited, obtaining a thorough family history is of tremendous importance in making a correct diagnosis. A detailed family tree should be completed to evaluate for evidence of autosomal dominant, autosomal recessive, and X-linked patterns of transmission. Questions regarding family members' use of canes or wheelchairs, skeletal deformities, or functional limitations are usually more informative than vague questions, such as asking whether any family members have a muscle disease. Identifying a particular hereditary pattern can not only help in correctly diagnosing the specific myopathy (Box 8) but is also of critical importance in providing appropriate genetic counseling.
Are There Precipitating Factors That Trigger Episodic Weakness or Stiffness?
A history of precipitating factors that might trigger or exacerbate symptoms of weakness or myotonia should be explored. It is important to ask patients if there is any history of using either illegal drugs or prescription medications that might produce a myopathy. Drugs that can cause toxic myopathies are listed in Box 9, and further discussion of this topic by Pasnoor, Barohn, and Dimachkie is found elsewhere in this issue. A history of weakness, pain, and/or myoglobinuria that is provoked by exercise might suggest the possibility of a glycolytic pathway defect. Episodes of weakness that occur in association with a fever would be supportive of a diagnosis of carnitine palmityl transferase deficiency. Periodic paralysis is characteristically provoked by exercise and ingestion of a carbohydrate meal followed by a period of rest. Patients with Involvement of organs or tissues other than muscle may also provide helpful clues in making the appropriate diagnosis. Cardiac disease (Box 10) may be associated with Andersen-Tawil syndrome, Duchenne or Becker muscular dystrophies, EmeryDreifuss muscular dystrophy, LGMD 1B (laminopathy), LGMD 2I (Fukutin related protein), LGMD 2C-F (sarcoglycanopathies), LGMD 2G (telethoninopathies), and myotonic dystrophy (types 1 and 2). Respiratory failure may be the presenting symptom of acid maltase deficiency, centronuclear myopathy, myotonic dystrophy, or nemaline myopathy (Box 11). Eventually, many myopathies will affect respiratory muscle strength, highlighting the need for consistent monitoring of pulmonary function studies throughout the disease course. Once symptoms of hypoventilation are evident, supportive care should be initiated with noninvasive positive pressure ventilation and assistive devices for clearance of upper airway secretions. Hepatomegaly may be seen in myopathies associated with deficiencies in acid maltase, carnitine, and debranching enzyme. The presence of cataracts, frontal balding, and mental retardation strongly suggests the diagnosis of myotonic dystrophy. Dysmorphic features may be associated with the congenital myopathies. The presence of a rash is extremely helpful in confirming the diagnosis of dermatomyositis. Musculoskeletal contractures can occur in many myopathies of a longstanding duration. However, contractures developing early in the course of the disease, especially at the elbows, can be a clue to Bethlem myopathy, Emery-Dreifuss dystrophy, and LGMD 1B (laminopathy). Evidence of diffuse systemic disease can indicate amyloidosis, sarcoidosis, an endocrinopathy, collagen-vascular disease, infectious disease, or a mitochondrial disorder.
What is the Distribution of Weakness?
In order to determine the distribution of muscle weakness, it is important to know which muscles to test and how to grade their power. Muscle strength can be tested by manual testing and from observation of functional activity (Box 12). Functional testing is particularly informative in young children who cannot usually cooperate with formal manual muscle testing and in adults with give-way weakness who present with complaints of muscle pain.
Assessment of muscle strength is usually based on the expanded Medical Research Council of Great Britain (MRC) grading scale of 0 to 5 (Box 13). In performing manual muscle testing of the upper extremities, it is necessary to assess shoulder abduction, external and internal rotation; elbow flexion and extension; wrist flexion and extension; and finger and thumb extension, flexion, and abduction. 5 Muscle groups that should be tested in the lower extremities include hip flexion, extension, and abduction; knee flexion and extension; ankle dorsiflexion, plantar flexion, inversion, and eversion; and toe extension and flexion. All muscle groups should be tested bilaterally and preferably against gravity. Neck flexors should be assessed in the supine position and neck extensors in the prone position. Knee extension and hip flexion should be tested in the seated position; knee flexion should be tested prone; and hip abduction should be tested in the lateral decubitus position. If testing against gravity is not done, the presence of significant muscle weakness can escape recognition.
The MRC grading system has being criticized because of the unequal width of response options. For instance, a one-point change from MRC 2 to 1 does not have the same significance as far as the amount of motor unit or muscle loss as a change from 5 to 4. Using Rasch analysis 6 in more than 1000 patients with a variety of neuromuscular disorders, disordered thresholds were demonstrated in 74% to 79% of the muscles examined, indicating the physicians' inability to discriminate between most MRC categories regardless of the physicians' experience or illness type. Thresholds were restored after rescoring the MRC grades from 6 to 4 options (0, paralysis; 1, severe weakness; 2, slight weakness; 3, normal strength). The modified MRC sum score acceptably fulfilled Rasch model expectations.
Finally, cranial nerve muscles such as the orbicularis oculi and oris, extraocular muscles, tongue, and palate should be examined. These muscles may be best tested by observation of functional activities such as asking patients to whistle, suck from a straw, and smile.
In addition to manual muscle testing and functional testing, muscles should be inspected for evidence of atrophy or hypertrophy. Atrophy of proximal limb muscles is common in most chronic myopathies. However, certain myopathies may demonstrate atrophy in specific groups that correspond to severe weakness in those muscles and provide additional diagnostic clues. For example, atrophy of the peri-scapular muscles associated with scapular winging is characteristic of facioscapulohumeral dystrophy. Scapular winging is also seen in patients with LGMD 1B (laminopathy), LGMD 2A (calpainopathy), Pompe disease, and LGMD 2C-F (sarcoglycanopathies). Selective atrophy of the quadriceps muscles and forearm flexor muscles is highly suggestive of inclusion body myositis. Distal myopathies may have profound atrophy of the anterior or posterior lower extremity compartments. However, muscles can show evidence of hypertrophy in some myotonic conditions, such as myotonia congenita. Muscle hypertrophy is also characterized by disorders including amyloidosis, sarcoidosis, and hypothyroid myopathy. In Duchenne and Becker dystrophy, the calf muscles demonstrate pseudohypertrophy caused by replacement with connective tissue and fat. Calf muscle hypertrophy is also characteristically seen in LGMD 2C-F (sarcoglycanopathies) early on in the course of Miyoshi myopathy and anoctamin-5 defect and in LGMD 2I (fukutin-related protein). In LGMD 2G (telethoninopathy), 50% of the patients will show calf hypertrophy and 50% will demonstrate calf atrophy. Focal muscle enlargement can also be caused by a neoplastic or inflammatory process, ectopic ossification, tendon rupture, or partial denervation. 
PATTERN RECOGNITION APPROACH TO MYOPATHIC DISORDERS
After answering the 6 key questions outlined earlier from the history and neurologic examination, one can attempt to classify a myopathic disorder into one of 10 distinctive patterns of muscle weakness, each with a specific differential diagnosis. The final diagnosis can then be confirmed based on information from a selective number of laboratory evaluations.
Pattern 1: Proximal Limb-Girdle Weakness
The most common pattern of muscle weakness in myopathies is symmetric weakness affecting predominantly the proximal muscles of the legs and arms or the so-called limb-girdle distribution. The distal muscles are usually involved but to a much lesser extent. Neck extensor and flexor muscles are also frequently affected. This pattern of weakness is seen in most hereditary and acquired myopathies and, therefore, is the least specific in arriving at a particular diagnosis.
Pattern 2: Distal Weakness
This pattern of weakness predominantly involves the distal muscles of the upper or lower extremities (anterior or posterior compartment muscle groups) (Box 14) (see the article by Dimachkie and Barohn elsewhere in this issue). Depending on the diagnosis and severity of disease, proximal muscles may also be affected. The involvement is usually, although not invariably, symmetric. Selective weakness and atrophy in distal extremity muscles is more commonly a feature of neuropathies; therefore, a careful sensory and reflex examination must always be performed in patients presenting with this phenotype. 
Pattern 4: Distal Arm/Proximal Leg Weakness
This pattern is associated with distal arm weakness involving the distal forearm muscles (wrist and finger flexors) and proximal leg weakness involving the knee extensors (quadriceps). The facial muscles are typically spared, and involvement of other muscles is extremely variable. In addition, the weakness is often asymmetric between the two sides, which is uncommon in most myopathies. This pattern is essentially pathognomonic for inclusion body myositis. For further discussion of this disease, the reader is referred to the article by Barohn and Dimachkie in this issue. This pattern may also represent an uncommon presentation of myotonic dystrophy; however, unlike inclusion body myositis, muscle weakness is symmetric. 68-year old with slowly progressive muscle weakness
A 68-year-old man without significant past medical history is referred for evaluation of slowly progressive muscle weakness for the past 5 years. His symptoms initially began with difficulty walking down stairs caused by his right knee giving out. He currently has difficulty arising from a chair and grasping objects with his right hand. He was evaluated by a neurologist 2 years ago whose work-up included a creatine phosphokinase (CPK) of 500 IU/L and a left quadriceps muscle biopsy that was consistent with polymyositis. The patient has been treated with a variety of immunosuppressive medications, including prednisone, methotrexate, and azathioprine, with continued progression of his weakness. The current examination reveals intact cranial nerves, sensation, and muscle stretch reflexes. Motor examination in the right upper extremity shows MRC grade 5 shoulder abduction, 5 elbow flexion/extension, 4 wrist flexion, 5 wrist extension, and 3À finger flexion. The strength in the left upper extremity is normal except for grade 41 finger flexion. In the left lower extremity, the patient exhibits grade 41 hip flexion, 31 knee extension, and 41 ankle dorsiflexion with thigh muscle atrophy. In the right lower extremity, the strength is normal except for grade 41 knee extension.
Comment
The chronic onset, asymmetric distribution of weakness, and selective involvement of wrist/finger flexion and knee extension is most consistent with a diagnosis of inclusion Pattern Approach to Myopathy body myositis (IBM). In many cases, the initial muscle biopsy fails to identify vacuoles; patients are inappropriately treated with immunosuppressant medications for presumptive polymyositis. In patients with a phenotype consistent with IBM, particularly if they are refractory to immunosuppressive treatment, a repeat biopsy may be necessary to clarify the diagnosis.
Pattern 5: Ptosis with or Without Ophthalmoparesis
Myopathies presenting with predominant involvement of ocular and/or pharyngeal muscles represent a relatively limited group of disorders (Box 16). The ocular involvement principally results in ptosis and ophthalmoparesis, which usually, although not always, occurs without symptoms of diplopia. Facial weakness is not uncommon; extremity weakness is extremely variable, depending on the diagnosis. The combination of ptosis, ophthalmoparesis without diplopia, and dysphagia should suggest the diagnosis of oculopharyngeal dystrophy, especially if there is a positive family history and the onset is in middle age or later. Ptosis and ophthalmoparesis without prominent pharyngeal involvement is a hallmark of many of the mitochondrial myopathies. Ptosis and facial weakness without ophthalmoparesis is a common feature of myotonic dystrophy and facioscapulohumeral dystrophy. Ptosis has diurnal variation in ocular myasthenia gravis and is often associated with diplopia.
70-year old with progressive dysphagia and weakness
A 70-year-old white woman with a family history of myasthenia gravis presents for the evaluation of a 10-year history of progressive dysphagia and weakness. She specifically denies any symptoms of diplopia and states that her symptoms do not fluctuate during the day or when she becomes fatigued. She has noted no improvement with a course of prednisone 60 mg/d and pyridostigmine 60 mg 4 times a day. Cranial nerve examination is remarkable for bilateral ptosis, incomplete abduction/adduction of both eyes, mild orbicularis oris weakness, and mild tongue weakness flexion. Sensory, cerebellar, and reflex examinations are normal. The work-up by a referring physician was remarkable for a creatine kinase (CK) of 350 IU/L and a negative acetylcholine receptor antibody.
Comment
The patient's distribution of weakness (ptosis, ophthalmoparesis, dysphagia, and proximal weakness), age of onset, and positive family history would be most suggestive of a diagnosis of oculopharyngeal muscular dystrophy (OPMD). The absence of symptoms of diplopia and muscle fatigue and the patient's slowly progressive course strongly argues against a diagnosis of a neuromuscular junction disorder, such as myasthenia gravis.
Pattern 6: Prominent Neck Extensor Weakness
This pattern is characterized by severe weakness of the neck extensor muscles. The term dropped head syndrome has been used in this situation (Box 17). Involvement of the neck flexors is variable. Extremity weakness depends on the diagnosis and may follow one of the previously outlined phenotypic patterns. For example, patients with a limb-girdle pattern of weakness may also have significant neck extensor involvement. Isolated neck extension weakness represents a distinct muscle disorder called isolated neck extensor myopathy (INEM). 8 Prominent neck extensor weakness is also common in 2 other neuromuscular diseases: amyotrophic lateral sclerosis and myasthenia gravis.
Pattern 7: Bulbar Weakness
Bulbar weakness (ie, tongue and pharyngeal weakness) is manifested by symptoms of dysarthria and dysphagia. Although several myopathies can have some bulbar involvement, the muscular dystrophy that has bulbar involvement as a primary manifestation is OPMD. Limb-girdle muscular dystrophy type 1A (myotilinopathy) can present with isolated bulbar weakness, and the inflammatory myopathies may rarely present in this manner. Neuromuscular junction disorders, such as myasthenia gravis and Lambert-Eaton myasthenic syndrome, also frequently have bulbar symptoms and signs. This pattern is considered an overlap pattern with amyotrophic lateral sclerosis and other motor neuron disorders that can have significant bulbar involvement. This pattern is characterized by a history of episodic pain, weakness, and myoglobinuria and may be related to a variety of conditions, many of which are not caused by an underlying muscle disorder (Box 18). When these symptoms are triggered by exercise, a metabolic myopathy is most likely. However, several patients may develop myoglobinuria because they are inactive individuals who are suddenly required to do an overwhelming amount of exercise (ie, the couch potato syndrome).
Pattern 9: Episodic Weakness Delayed or Unrelated to Exercise
This pattern applies to the disorders of periodic paralysis, both the genetic autosomal dominant channelopathies (Box 19) and the secondary periodic paralyses, such as those caused by thyrotoxicosis. Also, for completeness sake, it is reasonable to include the neuromuscular junction disorders in this pattern. In all of these conditions, the weakness can occur during or after exercise, or often the weakness is unrelated to physical exertion.
Pattern 10: Stiffness and Decreased Ability to Relax
This pattern includes all of the disorders that produce myotonia and paramyotonia and includes the hereditary disorders involving skeletal muscle sodium and chloride channels (Box 20, Table 1 ) as well as myotonic dystrophy types 1 and 2 (see the articles by Trivedi and Thornton elsewhere in this issue). Both myotonic dystrophies usually also have fixed muscle weakness, with predominantly distal weakness in myotonic dystrophy type 1 and proximal weakness in myotonic dystrophy type 2. The autosomal recessive form of chloride channelopathies, Becker disease, also has fixed proximal weakness. In addition, other less common disorders that fit this pattern include Brody disease, neuromyotonia, and the central nervous system disorder, stiff-person syndrome (see Table 1 ). Table 2 summarizes these 10 patterns of presentation of muscle disease. Once the key questions reviewed earlier have been answered and patients have been placed into one of these 10 patterns of weakness, laboratory studies can then be used to confirm the diagnosis.
LABORATORY APPROACH IN THE EVALUATION OF A SUSPECTED MYOPATHY CK
CK is an extremely useful laboratory study for the evaluation of patients with a suspected myopathy (Box 21). The CK is elevated in most patients with muscle disease but may be normal in slowly progressive myopathies. The degree of CK elevation can also be helpful in distinguishing different forms of muscular dystrophy. For example, in Duchenne dystrophy, the CK is invariably at least 10 times (and often up to 100 times) normal, whereas there are less significant elevations in most other myopathies. The other exceptions are LGMD 1C (caveolinopathy), 2A (calpainopathy), and 2B (dysferlinopathy) whereby CK may also be markedly elevated. The CK level may not be Pattern Approach to Myopathy Abbreviations: ALS, amyotrophic lateral sclerosis; CPT, carnitine palmityl transferase; FSH, facioscapulohumeral muscular dystrophy; LEMS, lambert-eaton myasthenic syndrome; MG, myasthenia gravis; OPMD, oculopharyngeal muscular dystrophy; PROMM, proximal myotonic myopathy. a Overlap pattern with neuropathy/motor neuron disease.
elevated in some myopathies or may even by lowered by several factors, including profound muscle wasting, corticosteroid administration, collagen diseases, alcoholism, or hyperthyroidism. It is also important to remember than an elevation of serum CK does not necessarily imply a primary myopathic disorder. Many times the CK will increase modestly (usually to <10 times normal) in motor neuron disease; uncommonly, CK elevations may be seen in Charcot-Marie-Tooth disease and Guillain-Barré syndrome. Endocrine disorders, such as hypothyroidism and hypoparathyroidism, can also be associated with high CK levels. The causes of CK elevation other than neuromuscular disease include muscle trauma (falls, intramuscular or subcutaneous injections, electromyography [EMG] studies), viral illnesses, seizures, or strenuous exercise. In these cases, CK elevations are usually transient and less than 5 times normal.
Race and sex can also affect serum CK (Box 22). CK levels are frequently more than the normal range in some black individuals and in patients with enlarged muscles. Occasionally, benign elevations of CK appear on a hereditary basis. It is extremely unusual for a slightly elevated CPK (3-fold or less) to be associated with an underlying myopathy in the absence of objective muscle weakness or pain. Recent data suggest that even higher cutoff values than those listed in Box 22 may be found in otherwise normal individuals based on sex and ethnicity. 9 For black men, an upper normal limit of 1201 IU/L was suggested, 621 for black women, and 504 nonblack men; the lowest cutoff is for nonblack women at 325 IU/L. In the absence of muscle weakness on examination, these patients can be observed as long as the history does not suggest a metabolic myopathy. 10 Serum tests for other muscle enzymes are significantly less helpful than the determination of the CK. Enzymes such as aldolase, aspartate aminotransferase (AST, serum glutamic-oxaloacetic transaminase), alanine aminotransferase (ALT, serum glutamic-pyruvic transaminase), and lactate dehydrogenase (LDH) may be slightly elevated in myopathies. Because AST, ALT, and LDH are often measured in screening chemistry panels, their elevation should prompt CK measurement to determine if the source is muscle or liver. If patients with an inflammatory myopathy are treated with an immunosuppressive agent that may cause hepatotoxicity, the liver-specific enzyme, gamma glutamic transferase, should be followed.
In general, CK isoenzymes are not helpful in evaluating myopathies. CK-MM elevations are typical of muscle disease, but CK-MB is also elevated in myopathies and does not indicate that cardiac disease is present.
Electrophysiologic Studies
Electrophysiologic studies, consisting of both nerve conduction studies (NCS) and EMG, should be part of the routine evaluation of patients with a suspected myopathy. 11, 12 These studies are helpful in confirming that the muscle is indeed the correct site of the lesion and that weakness is not the result of an underlying motor neuron disease, neuropathy, or neuromuscular junction disorder. NCS are typically normal in patients with myopathy except in distal myopathies. Needle EMG examination showing evidence of brief-duration, small-amplitude motor units with increased recruitment can be extremely helpful in confirming the presence of a myopathy. Needle EMG can also provide a clue as to which muscles have had recent or ongoing muscle injury and can be a guide as to which muscle to biopsy. It is important to realize, however, that the EMG can be normal in patients with myopathy; the results of electrodiagnostic studies need to be evaluated in the context of the patients' history, neurologic examination, and other laboratory studies.
The Muscle Biopsy
If the clinical features and/or electrodiagnostic features suggest the possibility of a myopathy, a muscle biopsy may be an appropriate test to confirm the diagnosis. However, many forms of hereditary muscle disorders can now be diagnosed with molecular genetic testing, eliminating the need for performing a muscle biopsy in every patient. A muscle specimen can be obtained through either an open or closed (needle or punch) biopsy procedure. The advantage of a needle or punch biopsy is that it is minimally invasive, is cosmetically more appealing, and multiple specimens can be obtained. The disadvantage of the closed biopsy procedure is that not all laboratories have the expertise to adequately process the muscle tissue acquired with this approach for all the necessary studies.
Selection of the appropriate muscle to biopsy is critical. Muscles that are severely weak (MRC grade 3 or less) should not be biopsied because the results are likely to only show evidence of end-stage muscle. In addition, muscles that have recently been studied by needle EMG should be avoided because of the possibility of artifacts created by needle insertion. Biopsies should generally be taken from muscles that demonstrate MRC grade 4 strength. For practical purposes, in the upper extremities, the muscles of choice are either the biceps or deltoid; in the lower extremities, the best choice is the vastus lateralis. The gastrocnemius should be avoided because its tendon insertion extends throughout the muscle and inadvertent sampling of a myotendinous junction may cause difficulty with interpretation. Occasionally, an imaging procedure, such as muscle ultrasound, computed tomography, or magnetic resonance imaging, can be used to guide the selection of the appropriate muscle to biopsy.
Biopsy specimens can be analyzed by light microscopy, electron microscopy, biochemical studies and immune staining (Box 23). In most instances, light microscopic observations of frozen muscle tissue specimens are sufficient to make a pathologic diagnosis. Typical myopathic abnormalities include central nuclei, both small and large hypertrophic round fibers, split fibers, and degenerating and regenerating fibers. Inflammatory myopathies are characterized by the presence of mononuclear inflammatory cells in the endomysial and perimysial connective tissue between fibers and occasionally around blood vessels. In addition, in dermatomyositis, atrophy of fibers located on the periphery of a muscle fascicle, perifascicular atrophy, is a common finding. Chronic myopathies frequently show evidence of increased connective tissue and fat.
For general histology, the hematoxylin and eosin and modified Gomori trichrome are the most useful. The latter is particularly helpful in identifying ragged-red fibers that 14 Electron microscopy (EM) evaluates the ultrastructural components of muscle fibers and is not required in most myopathies to make a pathologic diagnosis. EM is important, however, in the diagnosis of some congenital myopathies and mitochondrial disorders. Findings detected only by EM are seldom of clinical importance.
The muscle tissue can also be processed for biochemical analysis to determine a specific enzyme defect in the evaluation of a possible metabolic or mitochondrial myopathy. In addition, Western blot determinations from muscle tissue can be performed for certain muscle proteins. This type of analysis is usually limited to the dystrophin assays when the immune stains and the molecular genetic studies are inconclusive in establishing a diagnosis of either Duchenne or Becker dystrophy. This method has recently been expanded to calpainopathies and the dysferlin defect, though gene sequencing is more definitive.
Molecular Genetic Studies
The specific molecular genetic defect is now known for a large number of hereditary myopathies, and mutations can be identified by peripheral blood DNA analysis. Examples of molecular genetic studies that are commercially available are included in Box 24. This list is continually updated on www.genetests.org. Molecular genetic testing frequently eliminates the need for muscle biopsy. This technology is also extremely helpful for determining the carrier status and for performing prenatal testing. For Pompe disease, dry blood spot assay is a good screening test that must be followed by confirmation of acid alpha-glucosidase enzymatic activity in blood lymphocytes or other tissues (muscle or skin fibroblasts) or through gene sequencing (please refer to the article by Majed Dasouki and colleagues in this issue).
Other Tests
In addition to CK determinations, additional blood tests that can be extremely helpful in the evaluation of patients with a suspected myopathy include serum electrolytes, thyroid function tests, parathyroid hormone levels, vitamin D levels, and human immunodeficiency virus. In patients with an inflammatory myopathy, serologic determinations for systemic lupus erythematosus, rheumatoid arthritis, and other immunologic markers (eg, Jo-1 antibodies) can occasionally be useful. A urine analysis can also be performed to detect the presence of myoglobinuria. This condition should be suspected if the urine tests positive for blood but no red blood cells are identified. 10 Forearm exercise testing can often be an important part of the evaluation of patients with a suspected metabolic myopathy. The exercise test should be carried out without the blood pressure cuff because ischemic exercise may be hazardous in patients with defects in the glycolytic enzyme pathway. The test is performed by asking patients to perform isometric contractions using a handgrip dynamometer for 1.5 seconds separated by rest periods of 0.5 seconds for 1 minute. A resting blood sample for venous lactate and ammonia is obtained at baseline and subsequently at 1, 2, 4, 6, and 10 minutes following the completion of exercise. A 3-fold increase in the lactate level represents a normal response. The characteristic elevation of serum lactate after exercise is absent (phosphofructokinase deficiency, myophosphorylase deficiency) or reduced (phosphoglycerate mutase deficiency). Forearm testing is normal in all disorders of fat metabolism and is also in some glycolytic disorders with fixed muscle weakness, such as acid maltase deficiency.
SUMMARY
Although this pattern recognition approach to myopathy may have limitations, it can be extremely helpful in narrowing the differential diagnosis and, therefore, minimizing the number of laboratory studies that must be ordered to confirm the diagnosis. There will always be patients with muscle disease who will not fit neatly into any of these 10 categories. In addition, patients with involvement of other areas of the neuraxis, such as the motor neuron, peripheral nerve, or neuromuscular junction, may also frequently present with one of these patterns. For example, although proximal greater than distal weakness is most often seen in a myopathy, patients with acquired demyelinating neuropathies (Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy) often have proximal as well as distal muscle involvement. Careful consideration of the distribution of muscle weakness and attention to these common patterns of involvement in the context of other aspects of the neurologic examination and laboratory evaluation will usually, however, lead the clinician to a timely and accurate diagnosis.
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